A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD

Trial Profile

A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs QBW 251 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 22 Apr 2017 Status changed from recruiting to completed.
    • 03 Mar 2016 Planned End Date changed from 1 Oct 2016 to 1 Jan 2017 as per ClinicalTrials.gov record.
    • 03 Mar 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Jan 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top